Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Location(s): United States
SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for 12 months. SCORE2 is designed as a non-inferiority trial, with study eyes randomized to intravitreal bevacizumab (1.25 mg) every 4 weeks vs. intravitreal aflibercept (2.0 mg) every 4 weeks. SCORE2 aims to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with central retinal vein occlusion (CRVO), with the primary outcome of visual acuity measured at Month 6.